A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions
Type 2 Diabetes
Interventions
DRUG

Placebo

Tablets(n=4),once daily for 84 days

DRUG

50 mg SP2086

Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days

DRUG

100 mg SP2086

Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days

DRUG

200 mg SP2086

Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days

DRUG

100 mg Sitagliptin

Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days

Trial Locations (1)

Unknown

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT01969357 - A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes | Biotech Hunter | Biotech Hunter